SCHEMBL4672541

SCHEMBL4672541

Nc1ccc(Cc2csc(C(=O)C=C(O)C(=O)O)n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
ITGB1 P05556 3/20 0.36
ITGA5 P08648 3/20 0.36
AOC3 Q16853 3/20 0.35
ITGB3 P05106 2/20 0.34
ITGAV P06756 2/20 0.34
CACNA1G O43497 1/20 0.34
CACNA1H O95180 1/20 0.34
CACNA1I Q9P0X4 1/20 0.34
GABRA5 P31644 1/20 0.33
GABRB2 P47870 1/20 0.33
HSD17B10 Q99714 1/20 0.33
COPS5 Q92905 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PTGER1 P34995 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672538 1.00 HDAC1 (0.37) HDAC1HDAC6ITGB1ITGA5AOC3
SCHEMBL4675741 0.88 PTGER1 (0.41) HDAC1HDAC6L3MBTL1ALDH1A1TSHR
SCHEMBL4675737 0.88 PTGER1 (0.41) HDAC1HDAC6L3MBTL1ALDH1A1TSHR
SCHEMBL4676899 0.87 RAB9A (0.39) AOC3CACNA1GCACNA1HCACNA1IALDH1A1
SCHEMBL4676901 0.87 RAB9A (0.39) AOC3CACNA1GCACNA1HCACNA1IALDH1A1
SCHEMBL4671473 0.87 LMNA (0.42) HDAC1HDAC6AOC3CACNA1GCACNA1H
SCHEMBL4671477 0.87 LMNA (0.42) HDAC1HDAC6AOC3CACNA1GCACNA1H
SCHEMBL4676279 0.86 PTGER1 (0.33) HDAC1HDAC6AOC3CACNA1GCACNA1H
SCHEMBL4676282 0.86 PTGER1 (0.33) HDAC1HDAC6AOC3CACNA1GCACNA1H
SCHEMBL4676339 0.85 KMT2A (0.43) AOC3CACNA1GCACNA1HCACNA1IHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HDAC1 250/4885HDAC6 1000/4885ITGB1 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.